GIANT BIOGENE (02367) plans to repurchase shares based on the authorization to repurchase shares.

GIANT BIOGENE (02367) has issued an announcement regarding the proposed grant of a general mandate to repurchase shares. The Board of Directors hereby announces that it plans to exercise the power granted by the shareholders at the Company's Annual General Meeting held on June 13, 2025, to grant the Directors the authority to repurchase the Company's shares. Under the share repurchase mandate, the Company is authorized to repurchase up to 104 million shares, representing 10% of the number of issued shares (excluding treasury shares) as of the date of the resolution passed at the Annual General Meeting. This mandate will expire at the earliest of: (i) the conclusion of the next Annual General Meeting of the Company, or (ii) the date specified in the Articles of Association or other applicable laws for the expiration of the period for holding the next Annual General Meeting of the Company, or (iii) the date on which the share repurchase mandate is revoked or amended by the shareholders at a general meeting.